Correspondence on ‘Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine-learning-based model to assist the diagnosis of systemic lupus erythematosus’

We read the article by Adamichou et al, ‘Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine-learning-based model to assist the diagnosis of systemic lupus erythematosus’ with great interest. They proposed a machine-learning-based index (Systemic Lupus Erythematosus Risk Probability Index (SLERPI)) with 14 weighted items to predict the diagnosis of SLE. The original model gives SLE risk probabilities as definite SLE (87%–100%), likely SLE (44%–86%), possible/cannot rule out SLE (15%–43%) and unlikely SLE (0%–14%). The authors have also converted their model into a simple scoring system to facilitate its use in daily practice. Using their model on binary (SLE if score >7 and not SLE if ≤7), they reported a sensitivity of 94.2% and a specificity of 94.4% in their cohort. Since the original cohort was based on adult patients, we have tested the sensitivity of the SLERPI binary model was evaluated based on the features collected on standardised case report forms. The sensitivity and specificity of the SLERPI binary model was evaluated based on the features of the patients at the time of disease diagnosis.

The sensitivity and the specificity of the SLERPI binary model (with a cut-off value of 7) was 90% and 81.2%, respectively, in our cohort. The area under the receiver operating characteristic curve was 0.94 (figure 1) which indicates a good discrimination (SE: 0.012; 95% CI: 0.919 to 0.968). When we chose >8 as threshold, the sensitivity slightly decreased (from 90%) to 88.2%) while the specificity increased (from 81.2% to 89.4%). Thus, a threshold of 8 worked better in our cohort. Haematologic abnormalities such as thrombocytopenia or haemolytic anaemia and nephritis are more frequent among childhood patients than adults. Both lupus nephritis and haematologic features of SLE are the highest weighted items in the binary SLERPI model. This may be the reason for a higher threshold to perform better in the paediatric SLE patients.

Eleven SLE patients had a ≥7 score from SLERPI and were not classified with SLE. None of these patients had lupus nephritis or haematologic involvement. When we analysed the characteristics of controls misclassified with SLE by SLERPI (n=32), the most common diagnoses were haemolytic urticaria syndrome (HUS) and mixed connective tissue disease (MCTD). Patients with MCTD had similar clinical features with SLE and the differential diagnosis is challenging between MCTD and SLE in clinical practice. On the other hand, the haematologic manifestations that are common between HUS and SLE, which are highly weighted in the SLERPI model, were probably the main reasons for HUS misclassification as SLE. When we raised the threshold from 7 to 8, only 18 out of these 32 patients (56.3%) were misclassified with SLE. It was noteworthy that patients with MCTD and HUS were again misclassified with SLE by SLERPI model with the threshold of 8.

In conclusion, with the threshold set for adults, the SLERPI binary model yielded a low sensitivity and specificity in paediatric SLE cohort. However, this model can be useful in the paediatric practice when the threshold is set at >8.

Ezgi Deniz Batu, Ummusen Kaya Akca, Ozge Basaran, Yelda Bilginer, Seza Ozen

Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Correspondence to Ezgi Deniz Batu, Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara 06100, Turkey; ezgidenizbatu@yahoo.com

Twitter Seza Ozen @diseazoen

Contributors All authors were involved in drafting and revising the manuscript, and approved the final version. Study design: EDB, YB and SO. Data collection: EDB, UKA, YB and OB. Interpretation and analysis of the data: EDB, UKA, OB and SO.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.


Received 27 February 2021
Accepted 2 March 2021
Ann Rheum Dis 2021;0:1. doi:10.1136/annrheumdis-2021-220246

ORCID iDs
Ezgi Deniz Batu http://orcid.org/0000-0003-1065-2363
Seza Ozen http://orcid.org/0000-0003-2883-7668

REFERENCES